This study is a survey in Japan of Icatibant subcutaneous injection 30 mg syringe used to treat children or teenagers with acute attacks of hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Icatibant subcutaneous injection 30 mg syringe and to check if Icatibant subcutaneous injection 30 mg syringe improves acute attacks of HAE. During the study, pediatric participants with HAE will take Icatibant subcutaneous injection 30mg syringe according to their clinic's standard practice. The study doctors will check for side effects from Icatibant subcutaneous injection 30 mg syringe for 3 months.
Study Type
OBSERVATIONAL
Enrollment
32
Icatibant, 10 to 30 mg, Subcutaneous injection
Takeda selected site
Tokyo, Tokyo, Japan
Number of Participants who Experience at Least One Treatment-Emergent Adverse Events (TEAE)
Time frame: Up to 3 Months
Time from Onset of Seizure to Start of Treatment
Time from onset of seizure to the first drug administration will be assessed.
Time frame: Up to 3 Months
Time from First Drug Administration to Symptom Resolution
Time from the first drug administration to complete resolution of all symptoms of HAE will be assessed.
Time frame: Up to 3 Months
Duration of Seizure
The time from the start of the seizure to the disappearance of all symptoms will be assessed.
Time frame: Up to 3 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.